Ethicann Pharmaceuticals Inc. (Ethicann) is developing high-value cannabinoid-based ethical drugs. Our strategy is to reformulate approved drugs into safer, equally efficacious drugs using proprietary oral tablets (Zydis®, Catalent), and use an expedited regulatory path that reduces the traditional 7 - 12 year timeline to regulatory approval to a 3 - 5 year timeline. Ethicann will use this approach for several large-market disease indications. Our lead product, EPI-002, is a Zydis sublingual formulation (THC:CBD) for MS spasticity is targeted for Canadian approval in 2026 followed by market approval in UK, Germany and rest of Europe by 2028, and US approval in 2029. Ethicann pipeline of cannabinoid-based drugs includes treatments for epilepsy and chronic cancer pain. We are seeking co-development/commercialization partners for our pipeline products.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
